Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-leptin is an experimental gene therapy construct designed to deliver a functional leptin (LEP) gene using a recombinant adeno-associated virus (AAV) vector. It is primarily used in preclinical research to restore circulating leptin levels in models of congenital leptin deficiency, such as ob/ob mice. By providing a sustained source of leptin, the therapy aims to normalize metabolic abnormalities, including obesity, hyperglycemia, and insulin resistance. Research has also explored its role in intercepting obesity-mediated cancer progression, particularly in pancreatic cancer models. Various serotypes and targeting variants, such as adipose-targeting Rec2-leptin, have been investigated across multiple academic institutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV-leptin.